Latest News

Latest News

Interoperability Begins Where Data Exchange Ends

Interoperability Begins Where Data Exchange Ends

Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Section 232 Pharma Tariffs: What Changes on 29 September

Section 232 Pharma Tariffs: What Changes on 29 September

On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

read more
CBD Vaping: When Product Innovation Outpaces the Science

CBD Vaping: When Product Innovation Outpaces the Science

Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

read more
Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...

read more
The Future of Collagen Hydrogels in Regenerative Medicine

The Future of Collagen Hydrogels in Regenerative Medicine

Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...

read more
Section 232 Pharma Tariffs: What Changes on 29 September

Section 232 Pharma Tariffs: What Changes on 29 September

On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...

read more
CBD Vaping: When Product Innovation Outpaces the Science

CBD Vaping: When Product Innovation Outpaces the Science

Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...

read more
Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Neurodegeneration Pipeline 2026: Genetic Medicine Leads

Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...

read more
The Future of Collagen Hydrogels in Regenerative Medicine

The Future of Collagen Hydrogels in Regenerative Medicine

Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 07 September 2026

Weekly News Roundup | 07 September 2026

Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...

read more
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven

Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...

read more
New Biology, New Opportunities in Women’s Health

New Biology, New Opportunities in Women’s Health

Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...

read more
Clinical Trials Roundup | 4 Sept 2026

Clinical Trials Roundup | 4 Sept 2026

Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...

read more
The Scale-Up Test

The Scale-Up Test

A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...

read more
ACTO Achieves Veeva Gold Product Partner Status

ACTO Achieves Veeva Gold Product Partner Status

Validated integrations with Veeva applications help life sciences field teams train, practice, and execute with approved content and real time intelligence Toronto and New York, 2 September 2026 ACTO, uniting human intelligence with empathetic AI in life sciences,...

read more
Huntington Gene Therapy Submission Reaches FDA and MHRA

Huntington Gene Therapy Submission Reaches FDA and MHRA

uniQure filed for regulatory approval of its Huntington’s disease gene therapy on 2 September 2026. The Huntington gene therapy submission went to two agencies. One is the US Food and Drug Administration. The other is the UK Medicines and Healthcare products...

read more
GLP-1 Indications: The 2026 Regulatory Status Map

GLP-1 Indications: The 2026 Regulatory Status Map

The list of approved GLP-1 indications now reaches well beyond weight loss and glycaemic control. Regulators in three major markets have licensed the class across cardiology, nephrology and hepatology. Other conditions carry positive phase 3 data but no licence at...

read more

Further News

Why Women’s Health Innovation Needs Commercialisation Strategy

Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment. That...

A Regulatory Playbook for SaMD and Digital Health

Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...

Beyond Binding: Functional Prediction in GPCR Drug Discovery

In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...

An AI Mental Health App Is Not a Therapist: How to Build One Honestly

It's 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to...

Weekly News Roundup | 12 October 2026

Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...

Will the NHS Offer Atezolizumab for dMMR Colon Cancer?

Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....

Viatris Pacira Acquisition: What the $1.65bn Deal Buys

The Viatris Pacira acquisition buys Exparel and Zilretta for $1.65bn. See the assets, closing conditions, UK status and generic risks.

    GLP-1 Therapy: More Than Numbers on a Scale

    The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...

    Clinical Trial Results | 9 October 2026

    The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...

    Food and Medicines: Why the Leaflet and the Label Do Not Match

    Why closing the gap between clinical nutrition advice and the food labels in the supermarket aisle is a data problem before it is an education problem. Around 11 million deaths in 2017 were attributable to dietary risk factors, according to the Global Burden of...

    Petrelintide in Type 2 Diabetes: How Does It Compare?

    Zealand Pharma and Roche reported Phase 2b ZUPREME-2 data for petrelintide in type 2 diabetes. LSDN sets out the figures and the limits on comparing them with tirzepatide and semaglutide.

      More Data, Smarter AI: Is Life Sciences Making Better Decisions?

      The life sciences sector has always depended on the quality of evidence behind its decisions. Today, the volume of evidence, and the speed at which it can be analysed, is changing dramatically with artificial intelligence. In September, the National Commission into...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.